венозные тромбоэмболические осложнения, факторы риска, антикоагулянтная терапия, сулодексид, venous thrombolic complications, risk factors, anticoagulant therapy, sulodexide, Surgery, RD1-811

Venous thromboembolic complications (VTC) including deep veins thrombosis and pulmonary artery thromboembolia are sufficiently frequent but preventable states. In industrially developed countries 1-2 cases of VTC per 1 thousand persons per year are registered. In USA 900 thousand patients suffer from VTC annually. But these figures are most likely conservative as due to diffuseness of a clinical pattern and insufficient sensitivity of screening tests the frequency of verified VTC doesn't exceed 60-70% [1, 2].